{"entity":{"id":"temsirolimus","kind":"drug","name":"Temsirolimus","aka":[],"tldr":"A weekly infusion that was the first drug to extend survival in poor-risk kidney cancer (2007), and in 2024 the first targeted drug to improve outcomes in childhood rhabdomyosarcoma.","summary":"Global ARCC trial (NEJM 2007): OS 10.9 vs 7.3 months versus interferon in poor-risk metastatic RCC; approved 2007. Displaced in RCC by VEGF TKIs and immunotherapy. Approved in EU for relapsed mantle cell lymphoma (2009). COG ARST1431 (2024) showed improved event-free survival when added to VAC/VI in intermediate-risk rhabdomyosarcoma.","status":"approved","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Temsirolimus","links":[{"label":"Label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=temsirolimus"}],"tags":["gap-fill"],"related":[],"cancers":["rcc","rhabdomyosarcoma","mantle-cell-lymphoma"],"sections":[],"technologies":["kinase-inhibitors","pi3k-akt-mtor-inhibitors"],"targets":[],"drugs":[],"companies":["pfizer"],"institutions":[],"pathways":["pi3k-akt-mtor","hif-vhl"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Torisel","modality":"Intravenous mTOR inhibitor (rapamycin analogue)","mechanism":"Binds FKBP12 and allosterically inhibits mTORC1, reducing HIF-1α translation, cell growth and angiogenesis.","approvals":[{"region":"US","year":2007,"indication":"Advanced renal cell carcinoma"},{"region":"EU","year":2007,"indication":"Advanced RCC (poor risk); relapsed/refractory mantle cell lymphoma added 2009"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/temsirolimus/","neighbours":{"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"pecoma","kind":"cancer","name":"Perivascular epithelioid cell tumour (PEComa)","route":"/cancers/pecoma/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"rhabdomyosarcoma","kind":"cancer","name":"Rhabdomyosarcoma","route":"/cancers/rhabdomyosarcoma/"}],"technology":[{"id":"pi3k-akt-mtor-inhibitors","kind":"technology","name":"PI3K, AKT and mTOR inhibitors","route":"/technologies/pi3k-akt-mtor-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}],"pathway":[{"id":"pi3k-akt-mtor","kind":"pathway","name":"PI3K / AKT / mTOR","route":"/pathways/pi3k-akt-mtor/"},{"id":"renal-cell-carcinoma-signalling","kind":"pathway","name":"Renal cell carcinoma (KEGG map)","route":"/pathways/renal-cell-carcinoma-signalling/"},{"id":"hif-vhl","kind":"pathway","name":"VHL / HIF oxygen sensing","route":"/pathways/hif-vhl/"}],"drug":[{"id":"sirolimus","kind":"drug","name":"Sirolimus","route":"/drugs/sirolimus/"},{"id":"sirolimus-albumin-bound","kind":"drug","name":"Sirolimus protein-bound particles","route":"/drugs/sirolimus-albumin-bound/"}],"target":[{"id":"fkbp12","kind":"target","name":"FKBP12 (FKBP1A)","route":"/targets/fkbp12/"},{"id":"hif1a","kind":"target","name":"HIF-1α (HIF1A)","route":"/targets/hif1a/"},{"id":"mtor","kind":"target","name":"mTOR","route":"/targets/mtor/"},{"id":"setd2","kind":"target","name":"SETD2","route":"/targets/setd2/"}],"trial":[{"id":"anbl1221","kind":"trial","name":"ANBL1221","route":"/trials/anbl1221/"}],"paper":[{"id":"paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017","kind":"paper","name":"ANBL1221: irinotecan-temozolomide with temsirolimus or dinutuximab in relapsed or refractory neuroblastoma","route":"/key-papers/paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017/"}]}}